SCHEMBL452873

SCHEMBL452873

C1=Cc2ccccc2NNC1

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29774450 1.00 GAA (0.44) GAAMAPT
SCHEMBL29830729 0.78 GAA (0.44) GAAMAPT
SCHEMBL34295 0.77 GAA (0.48) GAAMAPT
SCHEMBL29415525 0.77 GAA (0.48) GAAMAPT
SCHEMBL3104669 0.77 GAA (0.37) GAAMAPT
SCHEMBL31079568 0.76 GAA (0.39) GAAMAPT
SCHEMBL8489461 0.76 GAA (0.46) GAAMAPT
SCHEMBL9683514 0.76 GAA (0.46) GAAMAPT
Potassium SCHEMBL9683518 0.76 GAA (0.46) GAAMAPT
Bromide SCHEMBL8857359 0.76 GAA (0.46) GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861128-A Polymerizable compound and optically anisotropic body 江苏创拓新材料有限公司 2021-12-31 CN claimed
EP-2961411-A2 METHODS OF TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION AND DISEASES WITH BROMODOMAIN INHIBITORS Washington University (US) 2016-01-06 EP claimed
US-20150366877-A1 METHODS OF TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION AND DISEASES WITH BROMODOMAIN INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-24 US claimed
WO-2014134583-A2 METHODS OF TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION AND DISEASES WITH BROMODOMAIN INHIBITORS WASHINGTON UNIVERSITY (US) 2014-09-04 WO claimed
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US claimed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US claimed
US-20090233913-A1 OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2009-09-17 US claimed
CN-101389600-A Optical isomers of dihydro-2, 3-benzodiazepine and its stereoselective synthesis EGYT GYOGYSZERVEGYESZETI GYAR (HU) 2009-03-18 CN claimed
EP-1979308-A1 OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS EGIS Gyógyszergyár Nyrt (HU) 2008-10-15 EP claimed
WO-2007077469-A1 OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS EGIS GYÓGYSZERGYÁR (HU) 2007-07-12 WO claimed
CN-1027505-C Process for preparing benzoheterocyclic compounds OTSUKA PHARMA CO LTD (JP) 1995-01-25 CN claimed
JP-52065287-A None JP disclosed
JP-52039690-A None JP disclosed
US-12637436-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2026-05-26 US disclosed
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2026-04-14 US disclosed
JP-S5239690-A PREPARATION OF BENZODIAZEPIN DERIVATIVES SUMITOMO CHEM CO LTD 1977-03-28 JP disclosed
US-4002611-A Preparation of benzodiazepines SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-01-11 US disclosed
US-3875142-A Process for preparing 2,3-dihydro-1H-benzodiazepine derivatives and their salts SUMITOMO CHEMICAL CO 1975-04-01 US disclosed
US-3875142-A Process for preparing 2,3-dihydro-1H-benzodiazepine derivatives and their salts SUMITOMO CHEMICAL CO 1975-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233913-A1 OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS GABRA2, GABRA3, GABRB2 GAA 2736/4885MAPT 1366/4885
US-20150366877-A1 METHODS OF TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION AND DISEASES WITH BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 GAA 1938/4885MAPT 2659/4885
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, HDHD5 GAA 1736/4885MAPT 4432/4885
US-12637436-B2 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof GRM3, GRM2, GRM1 GAA 4282/4885MAPT 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.